Browsing: dolutegravir (DTG)

For Jacqueline Wambui, a resident of Nairobi, living with the HIV virus has been a challenge. As an activist and a person living with the virus, she has gone through several treatment regimens as she manages her condition. However, none seem to have worked better than the new approved WHO recommended medication.

The World Health Organization recommends dolutegravir (DTG)-based treatment as the preferred first-line regimen for people living with HIV.

Jacque currently runs the Advocacy and Communications function at the network. Her educational background is in HIV counseling and training.

She is an HIV positive activist with a special interest in sexual and reproductive health for young HIV positive women and girls and advocating for their rights. Jacqueline was put on several different antiretroviral regimens, including d4T (stavudine), nevirapine and efavirenz before being switched to TLD (tenofovir/lamivudine/dolutegravir).

“The main differences dolutegravir (DTG) has made is that it has much fewer …